April 9 (Reuters) - C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type ...
Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
C4 Therapeutics Inc. CCCC shares rose in Thursday’s session after climbing as high as $3.66 in premarket trading. The company ...
InvestorsHub on MSN
C4 Therapeutics shares jump on expanded oncology collaboration with Roche
C4 Therapeutics (NASDAQ:CCCC) shares climbed about 10% after the company announced a broadened partnership with Roche (SIX:RO ...
GlobalData on MSN
C4 Therapeutics begins dosing in Phase Ib trial for multiple myeloma
The Phase Ib trial will enrol around 54 patients to study cemsidomide with elranatamab and dexamethasone.
More choices from one of our favorite e-bike makers More choices from one of our favorite e-bike makers is a deputy editor and Verge co-founder with a passion for human-centric cities, e-bikes, and ...
The first hard pull in the C8 ZR1 is genuinely shocking. Even without using a low gear, the thrust is violent. A proper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results